期刊文献+

去甲斑蝥素理化性质测定及大鼠在体肠吸收动力学研究

Study on the Physicochemical Properties and the Intestinal Absorption Kinetics of Norcantharidin in Rats
下载PDF
导出
摘要 目的测定去甲斑蝥素理化性质及在体肠吸收动力学,为设计缓释制剂提供参考依据。方法测定去甲斑蝥素溶解度、油水分配系数。采用大鼠在体回流方法,利用紫外分光光度法和HPLC分别测定酚红和去甲斑蝥素的含量,研究去甲斑蝥素在不同浓度和不同小肠区段下的吸收。结果去甲斑蝥素在十二指肠、空肠、回肠、结肠的吸收速率常数分别为:0.1623,0.1260,0.0084,0.0035h-1;在小肠的吸收速率常数不同药物浓度70、80、90μg.mL-1时分别为:0.0112,0.0056,0.0071h-1。结论不同的药物浓度对去甲斑蝥素在大鼠全肠道的吸收无显著影响,药物的吸收呈一级动力学过程,吸收机制为被动扩散,提示适于制备日服一次的缓释给药系统。 Objective To investigate physicochemical properties and the absorption kinetics of norcantharidin(NCTD) at different intestine segments in rats. Methods The dissolubility and n-octyl alcohol/water partition coefficient were determined. The intestine in rats was cannudated for in situ recirculation, UV and HPLC were respectively used to determine the concentrations of UV spectrums of phenol red and NCTD. The absorption of NCTD was studied at different intestine segments, and with different concentration of NCTD. Results The absorption rate constants(Ka) at duodenum, jejunum, ileum, and colon were 0.1623, 0.1260, 0.0084, 0.0035h-1 respectively. Ka from intestine at NCTD concentration of70, 80, 90μg·mL-1 were 0.0112, 0.0056, 0.0071h-1 respectively. Conclusion The concentration of NCTD had no distinctive effect on the absorption kinetics. The absorption of NCTD was a first-order process with passive diffusion mechanism, which indicated that NCTD could be prepared as sustained-release dosage form for administration once a day.
出处 《中国药物警戒》 2013年第1期5-7,共3页 Chinese Journal of Pharmacovigilance
基金 江苏省普通高校研究生科研创新计划项目(CXZZ11_0114) 苏州市科技计划项目(应用基础研究计划)(SYS201107)
关键词 去甲斑蝥素 理化性质 吸收动力学 在体肠回流法 norcantharidin physicochemical properties absorption kinetics intestinal recirculating method in situ
  • 相关文献

参考文献8

  • 1Xiaohua Liu,Wan Sia Heng,Paul. Novel polymeric microspheres containing norcantharidin for chemoembolization[J].Journal of Controlled Release,2006,(01):35-41.
  • 2王广生;李荣昌;窦培延.去甲斑蝥素在胃肠液中的存在状态[J]中国药学杂志,1984(08):24-26.
  • 3吴建梅,任天池.去甲斑蝥素脂质体的制备方法及理化性质研究[J].中国药学杂志,2005,40(19):1485-1489. 被引量:12
  • 4Yi-Chun Chen,Shi-Chuan Chang,Ming-Hsi Wu. Norcant-haridin reduced cyclins and cytokines production in human peripheral blood mononuclear cells[J].Life Sciences,2009.218-226.
  • 5Yu-Jen Chen,Wei-Min Chang,Yi-Wen Liu. A small-molecule metastasis inhibitor,norcantharidin,downregulates matrix metall-oproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells[J].Chemico-Biologica Interactions,2009,(03):440-446.doi:10.1016/j.cbi.2009.07.004.
  • 6Hui-Fen Liao,Yu-Jen Chen,Chin-Hung Chou. Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production[J].Toxicology inVitro,2011,(01):206-212.
  • 7Chunmin Wei,Yanni Teng,Benjie Wang. Separation and identification of norcantharidin metabolites in vivo by GC MS method[J].Journal of Chromatography,2011,(20):1741-1747.
  • 8Qin Wang,Liang Zhang,Wei Hu. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery[J].Nanomedicine:Nanotechnology Biology and Medicine,2010,(02):371-381.

二级参考文献9

  • 1程宇慧,廖工铁,侯世祥,李栗.去甲斑蝥酸钠白蛋白微球的研究[J].药学学报,1993,28(5):384-388. 被引量:12
  • 2潘卫三,孙稳健,胡晋.去甲斑蟊素毫微型胶囊制备方法的研究[J].沈阳药学院学报,1994,11(2):124-127. 被引量:10
  • 3王广生 李荣昌 窦培延.去甲斑蝥素在胃肠液中的存在状态.药学通报,1984,19(8):24-26.
  • 4王广生.斑蝥素水解及去甲基对其泌尿系统刺激的缓解[J].药学通报,1983,18(7):18-18.
  • 5Wang CS. MedicaL uses of mylabris in ancient and recent studies[ J].J Ethnopharmacol, 1989,26:147.
  • 6孙骏奇 甘哲 王丽娟.去甲斑蝥素对实验性肝炎的药理研究Ⅰ.对四氯化碳中毒性肝损伤的保护作用[J].北京第二医学院学报,1985,6(4):257-257.
  • 7温祥云 孙骏奇 甘哲.去甲斑蝥素对实验性肝炎的药理研究Ⅱ.去甲斑蝥素对正常肝脏毒性作用的病理形态学观察[J].北京第二医学院学报,1985,6(4):259-259.
  • 8董成.^3H—去甲斑蝥素在小鼠体内分布的研究[J].江西医学院学报,1984,(1):24-24.
  • 9梁福佑,张胜华,潘颖,徐琳娜,王维刚.去甲斑蝥素用于单克隆抗体为载体的肿瘤导向治疗实验研究[J].首都医科大学学报,1999,20(1):5-8. 被引量:22

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部